Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States

Our purpose was to evaluate the effect of PD-L1 testing on the cost-effectiveness of pembrolizumab for second-line treatment of advanced urothelial carcinoma in the bladder from the U.S. societal perspective.

Source: Urologic Oncology: Seminars and Original Investigations - December 6, 2018 Category: Urology & Nephrology Authors: Steven D. Criss, Davis T. Weaver, Deirdre F. Sheehan, Richard J. Lee, Pari V. Pandharipande, Chung Yin Kong Tags: Clinical-Bladder cancer Source Type: research